Drugs / RJK002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06454682 | Sep 2023 → Jun 2025 overdue | amyotrophic lateral sclerosis | RJK Biopharma Ltd | Active not recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06493279 | Sep 2024 → Nov 2026 expected | amyotrophic lateral sclerosis | RJK Biopharma Ltd | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RJK002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06493279 ↗ |
| Route | Intrathecal | “single intrathecal administration of investigational product” NCT06454682 ↗ |